377 related articles for article (PubMed ID: 30664790)
1. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy.
Carlson P; Dasgupta A; Grzelak CA; Kim J; Barrett A; Coleman IM; Shor RE; Goddard ET; Dai J; Schweitzer EM; Lim AR; Crist SB; Cheresh DA; Nelson PS; Hansen KC; Ghajar CM
Nat Cell Biol; 2019 Feb; 21(2):238-250. PubMed ID: 30664790
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.
Naume B; Synnestvedt M; Falk RS; Wiedswang G; Weyde K; Risberg T; Kersten C; Mjaaland I; Vindi L; Sommer HH; Sætersdal AB; Rypdal MC; Bendigtsen Schirmer C; Wist EA; Borgen E
J Clin Oncol; 2014 Dec; 32(34):3848-57. PubMed ID: 25366688
[TBL] [Abstract][Full Text] [Related]
3. The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings.
Shor RE; Dai J; Lee SY; Pisarsky L; Matei I; Lucotti S; Lyden D; Bissell MJ; Ghajar CM
Mol Oncol; 2022 Jan; 16(1):130-147. PubMed ID: 34058066
[TBL] [Abstract][Full Text] [Related]
4. IMMUNEPOTENT CRP plus doxorubicin/cyclophosphamide chemotherapy remodel the tumor microenvironment in an air pouch triple-negative breast cancer murine model.
Santana-Krímskaya SE; Franco-Molina MA; Zárate-Triviño DG; Prado-García H; Zapata-Benavides P; Torres-Del-Muro F; Rodríguez-Padilla C
Biomed Pharmacother; 2020 Jun; 126():110062. PubMed ID: 32172064
[TBL] [Abstract][Full Text] [Related]
5. In vivo anticancer synergy mechanism of doxorubicin and verapamil combination treatment is impaired in BALB/c mice with metastatic breast cancer.
McCarthy M; Auda G; Agrawal S; Taylor A; Backstrom Z; Mondal D; Moroz K; Dash S
Exp Mol Pathol; 2014 Aug; 97(1):6-15. PubMed ID: 24780744
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic heterogeneity of disseminated tumour cells is preset by primary tumour hypoxic microenvironments.
Fluegen G; Avivar-Valderas A; Wang Y; Padgen MR; Williams JK; Nobre AR; Calvo V; Cheung JF; Bravo-Cordero JJ; Entenberg D; Castracane J; Verkhusha V; Keely PJ; Condeelis J; Aguirre-Ghiso JA
Nat Cell Biol; 2017 Feb; 19(2):120-132. PubMed ID: 28114271
[TBL] [Abstract][Full Text] [Related]
7. Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.
Kim SJ; Jung KH; Son MK; Park JH; Yan HH; Fang Z; Kang YW; Han B; Lim JH; Hong SS
Cancer Lett; 2017 Sep; 403():339-353. PubMed ID: 28688971
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction between cyclophosphamide or paclitaxel and the bioreductive compound NLCPQ-1, in vivo.
Papadopoulou MV; Ji M; Bloomer WD
Oncol Res; 2003; 13(12):561-6. PubMed ID: 12899246
[TBL] [Abstract][Full Text] [Related]
9. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
[TBL] [Abstract][Full Text] [Related]
10. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of WAP-T mouse mammary carcinomas aggravates tumor phenotype and enhances tumor cell dissemination.
Jannasch K; Wegwitz F; Lenfert E; Maenz C; Deppert W; Alves F
Int J Cancer; 2015 Jul; 137(1):25-36. PubMed ID: 25449528
[TBL] [Abstract][Full Text] [Related]
12. Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells.
Sauer S; Reed DR; Ihnat M; Hurst RE; Warshawsky D; Barkan D
Front Oncol; 2021; 11():659963. PubMed ID: 33987095
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
15. Analysis of disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem cell like cells predict prognosis?
Chebouti I; Blassl C; Wimberger P; Neubauer H; Fehm T; Kimmig R; Kasimir-Bauer S
Oncotarget; 2016 May; 7(18):26454-64. PubMed ID: 27049920
[TBL] [Abstract][Full Text] [Related]
16. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
17. The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.
Shiozawa Y; Berry JE; Eber MR; Jung Y; Yumoto K; Cackowski FC; Yoon HJ; Parsana P; Mehra R; Wang J; McGee S; Lee E; Nagrath S; Pienta KJ; Taichman RS
Oncotarget; 2016 Jul; 7(27):41217-41232. PubMed ID: 27172799
[TBL] [Abstract][Full Text] [Related]
18. Tenascin-C increases lung metastasis by impacting blood vessel invasions.
Sun Z; Velázquez-Quesada I; Murdamoothoo D; Ahowesso C; Yilmaz A; Spenlé C; Averous G; Erne W; Oberndorfer F; Oszwald A; Kain R; Bourdon C; Mangin P; Deligne C; Midwood K; Abou-Faycal C; Lefebvre O; Klein A; van der Heyden M; Chenard MP; Christofori G; Mathelin C; Loustau T; Hussenet T; Orend G
Matrix Biol; 2019 Oct; 83():26-47. PubMed ID: 31288084
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of CTC and DTC-BM Detection for Adjuvant Therapy Effects and Prognosis Prediction in Early Breast Carcinoma: Results of 8-11 Years of Follow-up Evaluation.
Takeyama H; Shimada T; Kinoshita S; Uchida K
Ann Surg Oncol; 2017 May; 24(5):1227-1233. PubMed ID: 27909824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
